Uwe Liebchen and Michael Paal share first authorship.
The members of the Cyto-SOLVE study group are listed in the acknowledgements.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Dear Editor,
Hemadsorption techniques are used in critical care for numerous indications, although the evidence is often limited. One example is the elimination of ammonia with the cytokine adsorber Cytosorb® (adsorption based on hydrophobic interactions of substances with a molecular weight of 5–55 kDa). Most recently, in vitro and in vivo data postulated that Cytosorb® (combined with continuous kidney replacement therapy (CKRT)) could eliminate ammonia [1, 2]. Due to the physicochemical properties of ammonia, which is a 5 Da hydrophilic molecule, relevant adsorption by Cytosorb® is not to be expected [3]. If non-invasive therapeutic approaches fail (see supplementary material T1), ammonia can be eliminated by CKRT [4]. We present the results of the Cyto-SOLVE study which investigated the adsorption capacity of Cytosorb® for different substances (NCT04913298). In a subgroup-analysis, we investigated whether the use of Cytosorb® led to a relevant ammonia adsorption in intensive care unit (ICU)-patients with liver failure.
Anzeige
20 ICU-patients (14 male, median age: 53 years, median Simplified Acute Physiology Score II (SAPS-II) on therapy day: 78) with CKRT and hyperbilirubinemia (total bilirubin in serum > 10 mg/dL) were included (see supplementary material T2). Cytosorb® was installed primarily for bilirubin elimination and was integrated post-dialyzer into the CKRT circuit (supplementary Figure S1). Ammonia concentrations were measured at baseline, after six and twelve hours in different blood samples taken from arterial cannula or the CKRT circuit: arterial concentration (= blood in-flow line concentration pre-dialyzer), blood out-flow line concentration post-dialyzer (= pre-Cytosorb®), and blood out-flow line concentration post-Cytosorb®, respectively. The ammonia clearances of the dialyzer and Cytosorb® were calculated using the following formula:
T test with associated samples and Pearson correlation coefficient was used for statistical evaluation (see supplementary files T3, T4, and Table S1).
The median ammonia serum concentration at baseline was 77 µmol/L (Tables S2 and S3). There was a significant (p < 0.001) ammonia elimination by the dialyzer (pre- vs. post-dialyzer) at all time points with a median ammonia-clearance of 52, 42, and 42 mL/min, respectively. There was a significant correlation between ammonia-clearance and blood flow as well as effluent rate during therapy (p < 0.001, Tables S4 and T5). The median ammonia-clearances of Cytosorb® were at the same time points 4, -6, and -7 mL/min, with no significant elimination or correlation at any time (see T6). There was a significant (p < 0.001) decrease in ammonia-concentration during therapy (77 → 61 µmol/L). Figure 1 illustrates the ammonia-clearances of the dialyzer and Cytosorb® and ammonia-concentrations.
Fig. 1
Ammonia-clearance (mL/min) and -concentration (µmol/L) during therapy. Note: Green boxplots (always the first of the two boxplots) illustrate the ammonia clearance (mL/min) by the dialyzer and yellow boxplots show the ammonia clearance (mL/min) by Cytosorb®. Red boxplots present the ammonia plasma-concentrations at baseline, after six, and after 12 h with a significant decrease after six and twelve hours. The boxes of the boxplots represent the interquartile-range and the line the median. Whiskers were limited to 1.5 times of the interquartile range. The cross represents the mean
×
The elimination of ammonia was mainly achieved by the dialyzer with a constant clearance over time depending on blood flow and effluent rate [5]. In contrast, we saw no evidence for a relevant ammonia-clearance by Cytosorb®. Both Dominik et al. and Tomescu et al. combined Cytosorb® with hemodialysis. The decreased ammonia plasma-concentration, that was also observed in our population, can most likely be attributed to the dialyzer, and not, as postulated by Dominik et al., to Cytosorb®. One limiting factor of our study is that Cytosorb® was not primarily used for the elimination of ammonia. In addition, potential clinical benefits cannot be determined based on the study design. In conclusion, utilizing Cytosorb® in addition to CKRT is not suitable to lower ammonia concentrations.
Anzeige
Acknowledgements
Cyto-SOLVE study group: Sandra Frank, Antonia Greimel, Nils Maciuga, and Clara Brozat: Department of Anesthesiology, University Hospital, LMU Munich, Germany; Mathias Bruegel: Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany.
Declarations
Conflicts of interest
Upon manuscript submission, all authors declare they have no competing interests.
Ethics approval and consent to participate
Ethical approval was obtained from the ethical review committee of the Ludwig-Maximilians-Universität (registration number 21-0236).
Consent for publication
Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Anästhesiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes AINS, den Premium-Inhalten der AINS-Fachzeitschriften, inklusive einer gedruckten AINS-Zeitschrift Ihrer Wahl.
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.
Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
